NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free RNXT Stock Alerts $1.34 -0.04 (-2.90%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.4050-Day Range$1.04▼$1.7852-Week Range$0.53▼$4.60Volume17,338 shsAverage Volume55,840 shsMarket Capitalization$14.32 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get RenovoRx alerts: Email Address RenovoRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside534.3% Upside$8.50 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector802nd out of 938 stocksPharmaceutical Preparations Industry358th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingRenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, RenovoRx has a forecasted upside of 534.3% from its current price of $1.34.Amount of Analyst CoverageRenovoRx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.18% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 129.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNXT. Previous Next 2.5 News and Social Media Coverage News SentimentRenovoRx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RenovoRx this week, compared to 0 articles on an average week.Search Interest5 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovoRx has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About RenovoRx Stock (NASDAQ:RNXT)RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.Read More RNXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNXT Stock News HeadlinesMarch 12, 2024 | finance.yahoo.comRenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024March 10, 2024 | investing.comRenovoRx announces key leadership promotionsMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 8, 2024 | fr.investing.comRenovoRx annonce des promotions à des postes clésMarch 8, 2024 | finance.yahoo.comRenovoRx Highlights Key Leadership PromotionsFebruary 6, 2024 | fr.investing.comRenovoRx obtient un financement pour un essai de phase III sur le cancerJanuary 29, 2024 | msn.comRenovoRx closes $6.1M private placementJanuary 29, 2024 | finance.yahoo.comRenovoRx Closes $6.1 Million Private PlacementMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.December 21, 2023 | finance.yahoo.comRenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerDecember 19, 2023 | finance.yahoo.comRenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingDecember 13, 2023 | finance.yahoo.comRenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy PlatformDecember 9, 2023 | morningstar.comRenovoRx Inc RNXTNovember 16, 2023 | msn.comMaxim Group Downgrades RenovoRx (RNXT)November 16, 2023 | finance.yahoo.comRenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.November 14, 2023 | msn.comRenovoRx GAAP EPS of -$0.13November 14, 2023 | finance.yahoo.comRenovoRx Reports Third Quarter 2023 Financial Results and Operational HighlightsOctober 9, 2023 | finance.yahoo.comRenovoRx, Inc. (RNXT) Stock Historical Prices & Data - Yahoo FinanceOctober 2, 2023 | finance.yahoo.comRenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023August 18, 2023 | msn.comRoth MKM Maintains RenovoRx (RNXT) Buy RecommendationAugust 17, 2023 | finance.yahoo.comRenovoRx Reports Second Quarter 2023 Financial Results and Operational HighlightsJuly 31, 2023 | finance.yahoo.comRenovoRx to Present at the 43rd Annual Canaccord Genuity Growth ConferenceJuly 20, 2023 | finance.yahoo.comRenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) PlatformJuly 18, 2023 | barrons.comRenovoRx Inc.July 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Creative Medical Technology Holdings (CELZ), Boston Scientific (BSX) and RenovoRx (RNXT)July 11, 2023 | benzinga.comRenovoRx, Inc. Stock Presents A Compelling Value Proposition After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)July 5, 2023 | benzinga.comRenovoRx, Inc. Stock Surges After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)See More Headlines Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNXT CUSIPN/A CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+534.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-403.02% Return on Assets-197.48% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book1.97Miscellaneous Outstanding Shares10,690,000Free Float9,732,000Market Cap$14.32 million OptionableNot Optionable Beta1.12 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Ramtin Agah M.D. (Age 58)Founder, Chairman of Board & Chief Medical Officer Comp: $380.04kMr. Shaun R. Bagai (Age 47)CEO & Director Comp: $717.75kMs. Leesa Gentry (Age 54)Chief Clinical Officer Key CompetitorsVBI VaccinesNASDAQ:VBIVRedHill BiopharmaNASDAQ:RDHLABVC BioPharmaNASDAQ:ABVCNanoViricidesNYSE:NNVCEdesa BiotechNASDAQ:EDSAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 18,155 shares on 3/11/2024Ownership: 0.529%Vanguard Group Inc.Sold 18,155 shares on 2/15/2024Ownership: 0.529%Nixon Peabody Trust Co.Bought 97,165 shares on 2/9/2024Ownership: 0.909%Angela NelmsBought 1,100 shares on 10/3/2023Total: $1,155.00 ($1.05/share)View All Insider TransactionsView All Institutional Transactions RNXT Stock Analysis - Frequently Asked Questions Should I buy or sell RenovoRx stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RNXT shares. View RNXT analyst ratings or view top-rated stocks. What is RenovoRx's stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for RenovoRx's stock. Their RNXT share price targets range from $4.00 to $13.00. On average, they predict the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 534.3% from the stock's current price. View analysts price targets for RNXT or view top-rated stocks among Wall Street analysts. How have RNXT shares performed in 2024? RenovoRx's stock was trading at $2.29 on January 1st, 2024. Since then, RNXT shares have decreased by 41.5% and is now trading at $1.34. View the best growth stocks for 2024 here. Are investors shorting RenovoRx? RenovoRx saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 15,600 shares, an increase of 129.4% from the February 29th total of 6,800 shares. Based on an average daily trading volume, of 82,800 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the company's shares are short sold. View RenovoRx's Short Interest. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. Who are RenovoRx's major shareholders? RenovoRx's stock is owned by a number of institutional and retail investors. Top institutional investors include Nixon Peabody Trust Co. (0.91%), Vanguard Group Inc. (0.53%) and Vanguard Group Inc. (0.53%). Insiders that own company stock include Angela Nelms, Ramtin Agah and Shaun Bagai. View institutional ownership trends. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNXT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.